Skip To Main Content
Barbara Hero on Muck Rack

Barbara Hero

As seen in: Nature, Wiley Online Library, Frontiers, JAMA (The Journal of the American Medical Association), Science Magazine, EClinicalMedicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety and feasibility of oral zinc for patients with GNAO1 -related disorders (ZINCGNAO1): an open-label, single-arm, single-centre, pilot trial in Germany

|
By Petra Schiller, Barbara Hero, Vladimir L. Katanaev
| EClinicalMedicine Verified
Keywords GNAO1-related disorder Zinc acetate Safety and feasibility Paediatric movement disorders Developmental and epileptic encephalopathy Precision medicine Evidence before this study Evidence on GNAO1-related disorders (GNAO1-RD) is scarce.
Open in Who Shared Issue with article?

A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma

|
By Sveva Castelli, Tim Flaadt, Franziska Schulze, Felix Zirngibl, Lena Oevermann, Annette Künkele, Kathy Astrahantseff, Stefanie Schulte, Joerg Fuchs, Thorsten Simon, Barbara Hero, Julian Rogasch, Peter Lang, Steven W. Warmann, Arend von Stackelberg, Johannes H. Schulte, Angelika Eggert, Hedwig E. Deubzer, Theresa M. Thole-Kliesch, Louisa Duell, Patrick Hundsdoerfer
| Nature Verified
Abstract Very high-risk neuroblastoma is induction-refractory and often harbors mutations in RAS and/or p53 signaling combined with telomere maintenance mechanisms. Event-free survival is <20% in these children. Patients unable to mobilize sufficient hematopoietic stem cells to harvest for busulfan/melphalan-based high-dose chemotherapy before autologous transplantation are also at high risk for relapse.
Open in Who Shared Issue with article?

Status Quo analysis of an exercise therapy care model in pediatric oncology during acute therapy: perspectives from patients, parents, siblings, and staff

|
By Thorsten Simon, Barbara Hero, Dana Dougherty Reinke, Freerk Baumann, Amrei Friedrich, Nora Zoth
| Frontiers
Abstract Background: In oncological pediatrics, exercise therapy is still not part of regular medical care in Germany and exercise therapy projects are currently financed by charity organizations. Nevertheless, the scientific evidence for the benefit of exercise therapy in pediatric oncology has led to the implementation of exercise therapy programs at most of the German hospitals.
Open in Who Shared Issue with article?
See all 10 articles